Pub Date : 2026-03-01Epub Date: 2025-07-05DOI: 10.1016/j.jid.2025.05.040
Margherita Tiezzi , Charbel Haddad , Desli Shahini , Alya Mekouar , Patrizia Mancuso , Anne Van Praet , Anne-Sophie Sarkis , Farida Benhadou , Mathieu Daoud , Mariano Suppa , Steve Lemogoum , Elie Motulsky , Alessandra K. Cardozo , Véronique Del Marmol , Philippe van de Borne
{"title":"Exploring Vascular Homeostasis and Early Endothelial Damage in Hidradenitis Suppurativa: A Pilot Study on Erasmus Hospital Cohort","authors":"Margherita Tiezzi , Charbel Haddad , Desli Shahini , Alya Mekouar , Patrizia Mancuso , Anne Van Praet , Anne-Sophie Sarkis , Farida Benhadou , Mathieu Daoud , Mariano Suppa , Steve Lemogoum , Elie Motulsky , Alessandra K. Cardozo , Véronique Del Marmol , Philippe van de Borne","doi":"10.1016/j.jid.2025.05.040","DOIUrl":"10.1016/j.jid.2025.05.040","url":null,"abstract":"","PeriodicalId":16311,"journal":{"name":"Journal of Investigative Dermatology","volume":"146 3","pages":"Pages 822-826.e4"},"PeriodicalIF":5.7,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144577499","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-03-01Epub Date: 2025-10-25DOI: 10.1016/j.jid.2025.09.012
Anna L. Brinks , Carli D. Needle , Olivia D. Perez , Jerry Shapiro , Kristen I. Lo Sicco , Michael A. Occidental , Aristotelis Tsirigos , Lynn Petukhova
Disorders affecting the hair follicle (HF) and pilosebaceous unit impose psychosocial and financial burdens on patients and may signal risk for other medical conditions. Human genetic studies help to identify key physiological mechanisms that govern health and are increasingly used to improve drug development. GWASs identify genetic variants that are common in the population and implicate disease mechanisms that are widely shared among patients. In this study, we synthesize knowledge about the biology of the pilosebaceous unit that has been derived from GWASs of hair-related diseases. We identify the key genetic drivers and reveal fundamental biological themes that cut across diseases to identify crucial regulators of HF health.
{"title":"The Polygenic Architecture of Human Diseases Affecting the Hair Follicle","authors":"Anna L. Brinks , Carli D. Needle , Olivia D. Perez , Jerry Shapiro , Kristen I. Lo Sicco , Michael A. Occidental , Aristotelis Tsirigos , Lynn Petukhova","doi":"10.1016/j.jid.2025.09.012","DOIUrl":"10.1016/j.jid.2025.09.012","url":null,"abstract":"<div><div>Disorders affecting the hair follicle (HF) and pilosebaceous unit impose psychosocial and financial burdens on patients and may signal risk for other medical conditions. Human genetic studies help to identify key physiological mechanisms that govern health and are increasingly used to improve drug development. GWASs identify genetic variants that are common in the population and implicate disease mechanisms that are widely shared among patients. In this study, we synthesize knowledge about the biology of the pilosebaceous unit that has been derived from GWASs of hair-related diseases. We identify the key genetic drivers and reveal fundamental biological themes that cut across diseases to identify crucial regulators of HF health.</div></div>","PeriodicalId":16311,"journal":{"name":"Journal of Investigative Dermatology","volume":"146 3","pages":"Pages 602-612"},"PeriodicalIF":5.7,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145369422","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-03-01Epub Date: 2025-08-29DOI: 10.1016/j.jid.2025.08.022
Peng Sun , Christina N. Kraus , Wei Zhao , Jiahui Xu , Susie Suh , Quy Nguyen , Yunlong Jia , Arjun Nair , Melanie Oakes , Roberto Tinoco , Jessica Shiu , Bryan Sun , Ashley Elsensohn , Scott X. Atwood , Qing Nie , Xing Dai
Vulvar diseases are a neglected area of women's health, profoundly affecting patients’ QOL. Lichen sclerosus is a chronic inflammatory vulvar skin disorder leading to severe itching, pain, scarring, and an increased risk of malignancy. Despite this burden, the molecular pathogenesis of vulvar lichen sclerosus is not well-understood, limiting treatment options. In this study, we analyze lesional, nonlesional, and healthy vulvar skin using technologies including spatial and single-cell transcriptomics. Our findings identify unifying molecular changes across multiple cell types in lesional vulvar lichen sclerosus skin, including keratinocyte stress response, necroptosis, and basal/stem cell depletion. Chronic T-cell activation, enhanced cytotoxicity, aberrant cell-cell communication, and elevated IFN-γ/JAK/signal transducer and activator of transcription signaling were also observed. Functional studies suggest keratinocytes’ dual role as both targets of microenvironmental signaling (eg, IFN-γ) and sources of inflammatory alarmins (eg, S100A8/9). This work reveals keratinocytes as central players in vulvar lichen sclerosus pathogenesis and identifies potential biomarkers and therapeutic targets for future research.
{"title":"Spatial and Single-Cell Transcriptomics Reveal Keratinocytes as Key Players in Vulvar Lichen Sclerosus Pathogenesis","authors":"Peng Sun , Christina N. Kraus , Wei Zhao , Jiahui Xu , Susie Suh , Quy Nguyen , Yunlong Jia , Arjun Nair , Melanie Oakes , Roberto Tinoco , Jessica Shiu , Bryan Sun , Ashley Elsensohn , Scott X. Atwood , Qing Nie , Xing Dai","doi":"10.1016/j.jid.2025.08.022","DOIUrl":"10.1016/j.jid.2025.08.022","url":null,"abstract":"<div><div>Vulvar diseases are a neglected area of women's health, profoundly affecting patients’ QOL. Lichen sclerosus is a chronic inflammatory vulvar skin disorder leading to severe itching, pain, scarring, and an increased risk of malignancy. Despite this burden, the molecular pathogenesis of vulvar lichen sclerosus is not well-understood, limiting treatment options. In this study, we analyze lesional, nonlesional, and healthy vulvar skin using technologies including spatial and single-cell transcriptomics. Our findings identify unifying molecular changes across multiple cell types in lesional vulvar lichen sclerosus skin, including keratinocyte stress response, necroptosis, and basal/stem cell depletion. Chronic T-cell activation, enhanced cytotoxicity, aberrant cell-cell communication, and elevated IFN-γ/JAK/signal transducer and activator of transcription signaling were also observed. Functional studies suggest keratinocytes’ dual role as both targets of microenvironmental signaling (eg, IFN-γ) and sources of inflammatory alarmins (eg, S100A8/9). This work reveals keratinocytes as central players in vulvar lichen sclerosus pathogenesis and identifies potential biomarkers and therapeutic targets for future research.</div></div>","PeriodicalId":16311,"journal":{"name":"Journal of Investigative Dermatology","volume":"146 3","pages":"Pages 678-698.e5"},"PeriodicalIF":5.7,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144984716","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-03-01Epub Date: 2025-08-28DOI: 10.1016/j.jid.2025.08.021
Moira Shea , Alec Furst , Rama Abu Zanet , Iksha Kumar , Khoa Nguyen , Emile Latour , Alex G. Ortega-Loayza
{"title":"Use and Overuse of Diagnostic Imaging in Pyoderma Gangrenosum","authors":"Moira Shea , Alec Furst , Rama Abu Zanet , Iksha Kumar , Khoa Nguyen , Emile Latour , Alex G. Ortega-Loayza","doi":"10.1016/j.jid.2025.08.021","DOIUrl":"10.1016/j.jid.2025.08.021","url":null,"abstract":"","PeriodicalId":16311,"journal":{"name":"Journal of Investigative Dermatology","volume":"146 3","pages":"Pages 852-855"},"PeriodicalIF":5.7,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144984650","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-03-01Epub Date: 2026-03-09DOI: 10.1016/S0022-202X(26)00616-0
Edward Eid MD , Mark de Souza PhD , Anna Malyala PhD , Mei Chen PhD , David Woodley MD , Douglas Keene BS , Anna Bruckner MD , Wendy Chung MD, PhD , Kimberly Morel MD , Kathleen Peoples MS , Melissa Barriga BS , Joanne Carroll MSN , Laura Levin MD , Sanuj Ravindran MD, MBA , Ramsey Johnson MS , Michael Mangone PhD , Deborah Ramsdell MS , Hal Landy MD , Jean Tang MD, PhD , Alexander Nyström PhD
We evaluated the efficacy of intravenous PTR-01, a recombinant type VII collagen (C7) expressed in Chinese Hamster Ovary (CHO) cells, in a Phase 2 trial involving six patients with recessive dystrophic epidermolysis bullosa (RDEB). Results showed that PTR-01 was well-tolerated and improved wound healing; however, no anchoring fibrils (AFs) were detected at the basement membrane zone despite C7 deposition at the dermal-epidermal junction. To investigate this, we compared PTR-01 to fibroblast-derived wild-type C7. Non-reducing western blots showed additional low-molecular-weight bands in PTR-01, indicating reduced stability. Under reducing conditions, PTR-01 appeared as a doublet, with domain-specific antibodies revealing proteolytic maturation at the C-terminus in the NC2 domain. Proteomic analysis demonstrated altered glycosylation and a mixture of 40% wild-type C7 and 60% C7 containing a D1033Y substitution in the FN type III domain of NC1. This variant exhibited dominant-negative effects, reducing thermal stability and impairing binding to laminin-332 and collagen IV. These findings indicate that systemic C7 delivery to the skin is feasible and clinically beneficial in RDEB but suggest that impaired ligand binding, lower stability, and premature NC2 maturation hinder AF assembly. We have identified CHO clones that express only wild-type C7, which we plan to advance as an improved alternative to PTR-01.
{"title":"Enhancing the therapeutic potential of intravenous recombinant collagen VII as a protein replacement therapy for recessive dystrophic epidermolysis bullosa","authors":"Edward Eid MD , Mark de Souza PhD , Anna Malyala PhD , Mei Chen PhD , David Woodley MD , Douglas Keene BS , Anna Bruckner MD , Wendy Chung MD, PhD , Kimberly Morel MD , Kathleen Peoples MS , Melissa Barriga BS , Joanne Carroll MSN , Laura Levin MD , Sanuj Ravindran MD, MBA , Ramsey Johnson MS , Michael Mangone PhD , Deborah Ramsdell MS , Hal Landy MD , Jean Tang MD, PhD , Alexander Nyström PhD","doi":"10.1016/S0022-202X(26)00616-0","DOIUrl":"10.1016/S0022-202X(26)00616-0","url":null,"abstract":"<div><div>We evaluated the efficacy of intravenous PTR-01, a recombinant type VII collagen (C7) expressed in Chinese Hamster Ovary (CHO) cells, in a Phase 2 trial involving six patients with recessive dystrophic epidermolysis bullosa (RDEB). Results showed that PTR-01 was well-tolerated and improved wound healing; however, no anchoring fibrils (AFs) were detected at the basement membrane zone despite C7 deposition at the dermal-epidermal junction. To investigate this, we compared PTR-01 to fibroblast-derived wild-type C7. Non-reducing western blots showed additional low-molecular-weight bands in PTR-01, indicating reduced stability. Under reducing conditions, PTR-01 appeared as a doublet, with domain-specific antibodies revealing proteolytic maturation at the C-terminus in the NC2 domain. Proteomic analysis demonstrated altered glycosylation and a mixture of 40% wild-type C7 and 60% C7 containing a D1033Y substitution in the FN type III domain of NC1. This variant exhibited dominant-negative effects, reducing thermal stability and impairing binding to laminin-332 and collagen IV. These findings indicate that systemic C7 delivery to the skin is feasible and clinically beneficial in RDEB but suggest that impaired ligand binding, lower stability, and premature NC2 maturation hinder AF assembly. We have identified CHO clones that express only wild-type C7, which we plan to advance as an improved alternative to PTR-01.</div></div>","PeriodicalId":16311,"journal":{"name":"Journal of Investigative Dermatology","volume":"146 3","pages":"Page S20"},"PeriodicalIF":5.7,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147427086","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-03-01Epub Date: 2026-03-09DOI: 10.1016/S0022-202X(26)00578-6
Isha Gandhi BS , Robert Adler BA , Chase Fishman , Nicholas Dol BS , William Villasai , Steven Fishman MD
We analyzed publicly available genome-wide association study (GWAS) summary statistics from the FinnGen study, a large-scale Finnish biobank project correlating genetic variations with health data. The dataset included 171 ichthyosis cases, comprising lamellar, vulgaris and congenital subtypes, and 497,731 controls. Variants with p < 5 × 10-7 were considered suggestive. We identified two loci with suggestive associations to ichthyosis. The top SNP was located near the FLG gene (rs558269137; chromosome 1, position 152,312,600; CACTG→C) and demonstrated a strong association with ichthyosis (p=8.06 × 10-8, β = 1.63) that almost reached genome wide significance thresholds (p < 5 × 10-8). Two additional variants near PGLYRP3 demonstrated suggestive associations (p = 4.03 × 10-7). Ichthyosis has previously been linked to FLG, an essential component of the skin’s natural moisture barrier. However, its potential relationship to PGLYRP3 is novel and merits further exploration. PGLYRP3 encodes an immune receptor that binds bacterial peptidoglycan and is highly expressed in epithelial tissues, highlighting its role in mucosal antimicrobial defense. The non-significant but highly suggestive nature of our results may be due to misclassification of ichthyosis cases as controls in FinnGen, given its reliance on registered healthcare diagnoses and the high prevalence of the disease. Thus, our suggestive associations may offer insight into ichthyosis pathogenesis and therapeutic targets.
{"title":"Evaluation of the FLG and PGLYRP3 Loci in Ichthyosis: Evidence from Finnish population-scale genomic data","authors":"Isha Gandhi BS , Robert Adler BA , Chase Fishman , Nicholas Dol BS , William Villasai , Steven Fishman MD","doi":"10.1016/S0022-202X(26)00578-6","DOIUrl":"10.1016/S0022-202X(26)00578-6","url":null,"abstract":"<div><div>We analyzed publicly available genome-wide association study (GWAS) summary statistics from the FinnGen study, a large-scale Finnish biobank project correlating genetic variations with health data. The dataset included 171 ichthyosis cases, comprising lamellar, vulgaris and congenital subtypes, and 497,731 controls. Variants with p < 5 × 10<sup>-7</sup> were considered suggestive. We identified two loci with suggestive associations to ichthyosis. The top SNP was located near the FLG gene (rs558269137; chromosome 1, position 152,312,600; CACTG→C) and demonstrated a strong association with ichthyosis (p=8.06 × 10<sup>-8</sup>, β = 1.63) that almost reached genome wide significance thresholds (p < 5 × 10<sup>-8</sup>). Two additional variants near PGLYRP3 demonstrated suggestive associations (p = 4.03 × 10<sup>-7</sup>). Ichthyosis has previously been linked to FLG, an essential component of the skin’s natural moisture barrier. However, its potential relationship to PGLYRP3 is novel and merits further exploration. PGLYRP3 encodes an immune receptor that binds bacterial peptidoglycan and is highly expressed in epithelial tissues, highlighting its role in mucosal antimicrobial defense. The non-significant but highly suggestive nature of our results may be due to misclassification of ichthyosis cases as controls in FinnGen, given its reliance on registered healthcare diagnoses and the high prevalence of the disease. Thus, our suggestive associations may offer insight into ichthyosis pathogenesis and therapeutic targets.</div></div>","PeriodicalId":16311,"journal":{"name":"Journal of Investigative Dermatology","volume":"146 3","pages":"Page S11"},"PeriodicalIF":5.7,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147428430","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-03-01Epub Date: 2026-03-09DOI: 10.1016/S0022-202X(26)00623-8
Nikita Menta , Savanna Vidal , Adam Friedman
Background: Post-isotretinoin acne relapse rates remain significant, ranging from 20-60%. Despite these high rates, there are no standardized guidelines for post-isotretinoin acne management (PIAM). Objective: To evaluate PIAM strategies among experts. Methods: A survey assessing PIAM was emailed to the American Acne and Rosacea Society board of directors. Descriptive statistics were used for data analysis. Results: Of the 9 board members, 55.6% discontinue isotretinoin after reaching the intended cumulative dose and treating two months beyond clearance. Two-thirds of board members routinely initiate MTs, typically immediately after isotretinoin (66.7%). Topical retinoids (TRs) were the most common MT for both females (66.7%) and males (100%). To manage post-isotretinoin acne relapses, regimens most commonly included spironolactone (77.8%) and TRs (55.6%) in females, and a second course of isotretinoin (SCI) (55.6%) and TRs (55.6%) in males. Conclusions: There is significant variability in PIAM among experts. One-third of board members do not routinely initiate MT, pointing to differences in viewpoints on isotretinoin’s long-term efficacy. Another striking finding was the greater likelihood of initiating an SCI in males compared to females to treat post-isotretinoin acne relapses. Future directions include surveying a larger audience of dermatologists, including pediatric dermatologists. However, these data ultimately underscore the need for standardized PIAM guidelines.
{"title":"Post-Isotretinoin Acne Management: A Pilot Survey Study","authors":"Nikita Menta , Savanna Vidal , Adam Friedman","doi":"10.1016/S0022-202X(26)00623-8","DOIUrl":"10.1016/S0022-202X(26)00623-8","url":null,"abstract":"<div><div>Background: Post-isotretinoin acne relapse rates remain significant, ranging from 20-60%. Despite these high rates, there are no standardized guidelines for post-isotretinoin acne management (PIAM). Objective: To evaluate PIAM strategies among experts. Methods: A survey assessing PIAM was emailed to the American Acne and Rosacea Society board of directors. Descriptive statistics were used for data analysis. Results: Of the 9 board members, 55.6% discontinue isotretinoin after reaching the intended cumulative dose and treating two months beyond clearance. Two-thirds of board members routinely initiate MTs, typically immediately after isotretinoin (66.7%). Topical retinoids (TRs) were the most common MT for both females (66.7%) and males (100%). To manage post-isotretinoin acne relapses, regimens most commonly included spironolactone (77.8%) and TRs (55.6%) in females, and a second course of isotretinoin (SCI) (55.6%) and TRs (55.6%) in males. Conclusions: There is significant variability in PIAM among experts. One-third of board members do not routinely initiate MT, pointing to differences in viewpoints on isotretinoin’s long-term efficacy. Another striking finding was the greater likelihood of initiating an SCI in males compared to females to treat post-isotretinoin acne relapses. Future directions include surveying a larger audience of dermatologists, including pediatric dermatologists. However, these data ultimately underscore the need for standardized PIAM guidelines.</div></div>","PeriodicalId":16311,"journal":{"name":"Journal of Investigative Dermatology","volume":"146 3","pages":"Page S22"},"PeriodicalIF":5.7,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147428432","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-03-01Epub Date: 2026-03-09DOI: 10.1016/S0022-202X(26)00554-3
Daniela Mendoza Millan MD , Laura Ghanem , Bárbara Baptista Lopes , Martin Cevallos-Cueva , Devanie Martani , Cristina Sicorschi Gutu MD , Virginia Velasco-Tamariz MD , Peter Chien MD PhD
Ruxolitinib cream is currently FDA-approved for treating mild-to-moderate atopic dermatitis (AD) in patients ≥12 years, with a potential expansion to include children aged 2—11 years under active review. This updated systematic review and meta-analysis evaluated the efficacy and safety of ruxolitinib cream compared to vehicle, with a focus on age-based outcomes. We included 5 randomized controlled trials comprising 1912 patients aged 2—70 years. Subgroup analyses were performed for children (<12 years, n=265) versus adolescents/adults (≥12 years). Ruxolitinib significantly improved IGA-TS (RR 4.00, 95% CI 2.97—5.38) and EASI75 (RR 3.16, 95% CI 2.21—4.51) at 8 weeks. Both age groups showed significant benefit in IGA-TS (RR 3.43 in children vs. 5.07 in adolescents/adults) and EASI75 (RR 4.69 vs. 2.30), with no significant differences between groups. The incidence of TEAEs was unsignificantly increased in children (RR 1.14; p=0.55), while adolescents/adults showed a reduction (RR 0.83; p=0.04). However, some pediatric outcomes may reflect limited statistical power due to the smaller sample size compared to broader adult data. These findings support the expanding role of topical ruxolitinib as a non-steroidal, well-tolerated option for pediatric AD. As the FDA evaluates its use in children as young as 2 years, our results highlight the need for further high-powered pediatric trials, long-term safety studies, and real-world data to guide age-appropriate clinical use.
Ruxolitinib乳膏目前已被fda批准用于治疗≥12岁患者的轻中度特应性皮炎（AD），并有可能扩大到2-11岁的儿童，目前正在积极审查中。这一更新的系统综述和荟萃分析评估了ruxolitinib乳膏与对照剂相比的疗效和安全性，重点是基于年龄的结果。我们纳入了5项随机对照试验，包括1912名年龄在2-70岁的患者。对儿童（12岁，n=265）和青少年/成人（≥12岁）进行亚组分析。Ruxolitinib在8周时显著改善IGA-TS （RR 4.00, 95% CI 2.97-5.38）和EASI75 （RR 3.16, 95% CI 2.21-4.51）。两个年龄组在IGA-TS（儿童RR为3.43，青少年/成人RR为5.07）和EASI75 （RR为4.69，青少年/成人RR为2.30）方面均有显著获益，组间无显著差异。儿童teae发生率无显著升高（RR = 1.14; p=0.55），而青少年/成人发生率降低（RR = 0.83; p=0.04）。然而，与广泛的成人数据相比，由于样本量较小，一些儿科结果可能反映出有限的统计效力。这些发现支持外用ruxolitinib作为一种非甾体、耐受性良好的儿科AD治疗选择的作用扩大。由于FDA评估其在2岁以下儿童中的使用，我们的结果强调需要进一步的高强度儿科试验，长期安全性研究和实际数据来指导适合年龄的临床使用。
{"title":"Assessing Topical Ruxolitinib for Atopic Dermatitis Across Age Groups: A Meta-Analysis of Pediatric and Adult Data","authors":"Daniela Mendoza Millan MD , Laura Ghanem , Bárbara Baptista Lopes , Martin Cevallos-Cueva , Devanie Martani , Cristina Sicorschi Gutu MD , Virginia Velasco-Tamariz MD , Peter Chien MD PhD","doi":"10.1016/S0022-202X(26)00554-3","DOIUrl":"10.1016/S0022-202X(26)00554-3","url":null,"abstract":"<div><div>Ruxolitinib cream is currently FDA-approved for treating mild-to-moderate atopic dermatitis (AD) in patients ≥12 years, with a potential expansion to include children aged 2—11 years under active review. This updated systematic review and meta-analysis evaluated the efficacy and safety of ruxolitinib cream compared to vehicle, with a focus on age-based outcomes. We included 5 randomized controlled trials comprising 1912 patients aged 2—70 years. Subgroup analyses were performed for children (<12 years, n=265) versus adolescents/adults (≥12 years). Ruxolitinib significantly improved IGA-TS (RR 4.00, 95% CI 2.97—5.38) and EASI75 (RR 3.16, 95% CI 2.21—4.51) at 8 weeks. Both age groups showed significant benefit in IGA-TS (RR 3.43 in children vs. 5.07 in adolescents/adults) and EASI75 (RR 4.69 vs. 2.30), with no significant differences between groups. The incidence of TEAEs was unsignificantly increased in children (RR 1.14; p=0.55), while adolescents/adults showed a reduction (RR 0.83; p=0.04). However, some pediatric outcomes may reflect limited statistical power due to the smaller sample size compared to broader adult data. These findings support the expanding role of topical ruxolitinib as a non-steroidal, well-tolerated option for pediatric AD. As the FDA evaluates its use in children as young as 2 years, our results highlight the need for further high-powered pediatric trials, long-term safety studies, and real-world data to guide age-appropriate clinical use.</div></div>","PeriodicalId":16311,"journal":{"name":"Journal of Investigative Dermatology","volume":"146 3","pages":"Page S5"},"PeriodicalIF":5.7,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147428567","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-03-01Epub Date: 2025-09-02DOI: 10.1016/j.jid.2025.08.027
Allison Clatch , Jason A. Trubiano
{"title":"Analysis of Skin Immune Cells in Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis","authors":"Allison Clatch , Jason A. Trubiano","doi":"10.1016/j.jid.2025.08.027","DOIUrl":"10.1016/j.jid.2025.08.027","url":null,"abstract":"","PeriodicalId":16311,"journal":{"name":"Journal of Investigative Dermatology","volume":"146 3","pages":"Pages 830-834.e5"},"PeriodicalIF":5.7,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145002362","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号